ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Thyrocare reports robust 24% growth, pivoting from volume-led routine testing to specialized diagnostics under new management. High operational leverage is evident as PAT growth significantly outpaced revenue.
Q2 FY27 consolidated revenue ₹270.8 Cr (+25.1%), EBITDA ₹89.3 Cr (33.0% margin), PAT before exceptions ₹60.2 Cr (+25.7%). Debt-free; NHL radiology divestment pending.
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
Thyrocare delivered strong Q1 FY27 results with 24% YoY consolidated revenue growth and 34% YoY PAT growth, driven by pathology network expansion and high-value specialty test launches.
Thyrocare reports strong Q4 FY26 results with 20% consolidated revenue growth and 128% PAT surge, driven by volume growth and core pathology expansion.
Thyrocare reports strong performance for Q4FY26 and FY26 with significant YoY growth in PAT and EBITDA driven by network expansion and operational efficiencies.
Thyrocare reports robust growth for Q4FY26 and FY26, driven by franchise expansion and new specialty launches like Genomics and Allergy testing.